Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.Don't Miss Our New Year's Offers:Discover the latest stocks ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $4,177.57 today based on a ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...